Myriad Genetics Inc (MYGN)

Pretax margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	-123,400	-116,600	-156,600	-235,500	-262,200	-282,000	-265,000	-166,800	-140,600	-132,000	-48,000	-33,900	-57,100	-69,300	-152,800	-207,500	-289,000	-244,700	-223,300	-172,500
Revenue (ttm)	US$ in thousands	837,600	823,600	802,200	774,200	753,200	734,400	698,900	694,700	678,400	661,400	672,300	682,400	690,600	684,400	662,300	566,100	557,000	597,500	638,600	760,800
Pretax margin		-14.73%	-14.16%	-19.52%	-30.42%	-34.81%	-38.40%	-37.92%	-24.01%	-20.73%	-19.96%	-7.14%	-4.97%	-8.27%	-10.13%	-23.07%	-36.65%	-51.89%	-40.95%	-34.97%	-22.67%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-123,400K ÷ $837,600K
= -14.73%

The pretax margin for Myriad Genetics Inc shows a fluctuating trend over the analyzed period. It started with a negative margin of -22.67% in March 2020 and saw a downward trend, reaching its lowest point at -51.89% in December 2020. Subsequently, there was a gradual improvement in the pretax margin, with fluctuations along the way.

The company managed to reduce its negative pretax margin to -8.27% by December 2021, showing signs of recovery. However, the margin deteriorated again in the subsequent periods. By June 2022, it decreased to -7.14%, and by September 2022, it further declined to -19.96%.

The trend continued to be volatile, with fluctuations in the pretax margin. By December 2024, the pretax margin stood at -14.73%. Overall, the company faced challenges in maintaining a positive pretax margin throughout the analyzed period, indicating potential financial difficulties and a need for strategic management to improve profitability.